These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 11289076

  • 1. A multivariate insight into the in vitro antitumour screen database of the National Cancer Institute: classification of compounds, similarities among cell lines and the influence of molecular targets.
    Musumarra G, Condorelli DF, Costa AS, Fichera M.
    J Comput Aided Mol Des; 2001 Mar; 15(3):219-34. PubMed ID: 11289076
    [Abstract] [Full Text] [Related]

  • 2. Shortcuts in genome-scale cancer pharmacology research from multivariate analysis of the National Cancer Institute gene expression database.
    Musumarra G, Condorelli DF, Scire S, Costa AS.
    Biochem Pharmacol; 2001 Sep 01; 62(5):547-53. PubMed ID: 11585051
    [Abstract] [Full Text] [Related]

  • 3. Mining and visualizing large anticancer drug discovery databases.
    Shi LM, Fan Y, Lee JK, Waltham M, Andrews DT, Scherf U, Paull KD, Weinstein JN.
    J Chem Inf Comput Sci; 2000 Sep 01; 40(2):367-79. PubMed ID: 10761142
    [Abstract] [Full Text] [Related]

  • 4. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action.
    Huang R, Wallqvist A, Thanki N, Covell DG.
    Pharmacogenomics J; 2005 Sep 01; 5(6):381-99. PubMed ID: 16103895
    [Abstract] [Full Text] [Related]

  • 5. An information-intensive approach to the molecular pharmacology of cancer.
    Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paull KD.
    Science; 1997 Jan 17; 275(5298):343-9. PubMed ID: 8994024
    [Abstract] [Full Text] [Related]

  • 6. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
    Fojo T, Farrell N, Ortuzar W, Tanimura H, Weinstein J, Myers TG.
    Crit Rev Oncol Hematol; 2005 Jan 17; 53(1):25-34. PubMed ID: 15607933
    [Abstract] [Full Text] [Related]

  • 7. Data mining the NCI cancer cell line compound GI(50) values: identifying quinone subtypes effective against melanoma and leukemia cell classes.
    Marx KA, O'Neil P, Hoffman P, Ujwal ML.
    J Chem Inf Comput Sci; 2003 Jan 17; 43(5):1652-67. PubMed ID: 14502500
    [Abstract] [Full Text] [Related]

  • 8. Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: predicting biochemical mechanism of action.
    Koutsoukos AD, Rubinstein LV, Faraggi D, Simon RM, Kalyandrug S, Weinstein JN, Kohn KW, Paull KD.
    Stat Med; 2003 Jan 17; 13(5-7):719-30. PubMed ID: 8023045
    [Abstract] [Full Text] [Related]

  • 9. Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity.
    Shi LM, Myers TG, Fan Y, O'Connor PM, Paull KD, Friend SH, Weinstein JN.
    Mol Pharmacol; 1998 Feb 17; 53(2):241-51. PubMed ID: 9463482
    [Abstract] [Full Text] [Related]

  • 10. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics.
    Yamori T.
    Cancer Chemother Pharmacol; 2003 Jul 17; 52 Suppl 1():S74-9. PubMed ID: 12819939
    [Abstract] [Full Text] [Related]

  • 11. Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data.
    Wallqvist A, Rabow AA, Shoemaker RH, Sausville EA, Covell DG.
    Bioinformatics; 2003 Nov 22; 19(17):2212-24. PubMed ID: 14630650
    [Abstract] [Full Text] [Related]

  • 12. Mining the NCI anticancer drug discovery databases: genetic function approximation for the QSAR study of anticancer ellipticine analogues.
    Shi LM, Fan Y, Myers TG, O'Connor PM, Paull KD, Friend SH, Weinstein JN.
    J Chem Inf Comput Sci; 1998 Nov 22; 38(2):189-99. PubMed ID: 9538518
    [Abstract] [Full Text] [Related]

  • 13. Correlations between the activities of 19 anti-tumor agents and the intracellular glutathione concentrations in a panel of 14 human cancer cell lines: comparisons with the National Cancer Institute data.
    Bracht K, Boubakari, Grünert R, Bednarski PJ.
    Anticancer Drugs; 2006 Jan 22; 17(1):41-51. PubMed ID: 16317289
    [Abstract] [Full Text] [Related]

  • 14. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
    Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, Bates SE.
    Mol Pharmacol; 1994 Oct 22; 46(4):627-38. PubMed ID: 7969041
    [Abstract] [Full Text] [Related]

  • 15. Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening data.
    Covell DG, Huang R, Wallqvist A.
    Mol Cancer Ther; 2007 Aug 22; 6(8):2261-70. PubMed ID: 17699723
    [Abstract] [Full Text] [Related]

  • 16. Methyl protogracillin (NSC-698792): the spectrum of cytotoxicity against 60 human cancer cell lines in the National Cancer Institute's anticancer drug screen panel.
    Hu K, Yao X.
    Anticancer Drugs; 2001 Jul 22; 12(6):541-7. PubMed ID: 11460001
    [Abstract] [Full Text] [Related]

  • 17. A novel approach for the virtual screening and rational design of anticancer compounds.
    Estrada E, Uriarte E, Montero A, Teijeira M, Santana L, De Clercq E.
    J Med Chem; 2000 May 18; 43(10):1975-85. PubMed ID: 10821710
    [Abstract] [Full Text] [Related]

  • 18. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program.
    Tew KD, Monks A, Barone L, Rosser D, Akerman G, Montali JA, Wheatley JB, Schmidt DE.
    Mol Pharmacol; 1996 Jul 18; 50(1):149-59. PubMed ID: 8700107
    [Abstract] [Full Text] [Related]

  • 19. Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.
    Huang R, Wallqvist A, Covell DG.
    J Med Chem; 2006 Mar 23; 49(6):1964-79. PubMed ID: 16539384
    [Abstract] [Full Text] [Related]

  • 20. Thymidylate synthase as a molecular target for drug discovery using the National Cancer Institute's Anticancer Drug Screen.
    Parr AL, Myers TG, Holbeck SL, Loh YJ, Allegra CJ.
    Anticancer Drugs; 2001 Aug 23; 12(7):569-74. PubMed ID: 11487712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.